Regulatory considerations for developing remote measurement technologies for Alzheimer’s disease research-Reference-Cited by-同舟云学术

Regulatory considerations for developing remote measurement technologies for Alzheimer’s disease research

Published:2024-09-04 Issue:1 Volume:7 Page:
ISSN:2398-6352
Container-title:npj Digital Medicine
language:en
Short-container-title:npj Digit. Med.

Author:

Erdemli Gül^ORCID,Grammatikopoulou Margarita,Wagner Bertil,Vairavan Srinivasan^ORCID,Curcic Jelena^ORCID,Aarsland Dag^ORCID,Wittenberg Gayle^ORCID,Nikolopoulos Spiros,Muurling Marijn,Froehlich Holger^ORCID,de Boer Casper,Shanbhag Niraj M.,Nies Vera J. M.,Coello Neva^ORCID,Gove Dianne,Diaz Ana,Foy Suzanne,Dartee Wim,Brem Anna-Katharine^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41746-024-01211-8.pdf

Reference30 articles.

1. DeTure, M. A. & Dickson, D. W. The neuropathological diagnosis of Alzheimer’s disease. Mol. Neurodegener. 14, 32 (2019).

2. Dubois, B. et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 12, 292–323 (2016).

3. Piau, A., Wild, K., Mattek, N. & Kaye, J. Current state of digital biomarker technologies for real-life, home-based monitoring of cognitive function for mild cognitive impairment to mild Alzheimer disease and implications for clinical care: systematic review. J. Med. Internet Res. 21, e12785 (2019).

4. Brem, A. K. et al. Digital endpoints in clinical trials of Alzheimer’s disease and other neurodegenerative diseases: challenges and opportunities. Front Neurol. 14, 1210974 (2023).

5. Kaye, J. et al. Using digital tools to advance Alzheimer’s drug trials during a pandemic: The EU/US CTAD Task Force. J. Prev. Alzheimers Dis. 8, 513–519 (2021).